

in association with



society of hematologic oncology

promoted by



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico



With the patronage of



ALLEANZA
CONTRO
IL CANCRO



SCHOOL ACUTE LEUKEMIA

Clinical And Biological

www.sohoitaly.it

JOIN US!



@sohoitaly

#SOHOitLEUKEMIA

15 16 17 March 2021

C. Cerchione N. Daver A. De La Fuente E. Jabbour H. Kantarjian
M. Konopleva F. Locatelli G. Martinelli F. Ravandi

Virtual Event

Registration



Organizing secretariat



www.proeventi.it

20 CME (ECM) HEMATOLOGISTS, ONCOLOGISTS, PATHOLOGIST, BIOLOGISTS



SCHOOL ACUTE LEUKEMIA

Clinical And Biological

15 16 17 March 2021

Virtual Event

Presidents:

Cerchione C, Martinelli G, Kantarjian H

Scientific Board:

Cerchione C, Martinelli G, Locatelli F, Daver N, De La Fuente A, Jabbour E, Kantarjian H, Konopleva M, Ravandi F

Scientific Secretariat:

Cerchione C, Martinelli G, Locatelli F, Daver N, Jabbour E, Kantarjian H, Konopleva M, Ravandi F, Giannini B, Musuraca G, Norata M

Big Faculty:

Cerchione C, Martinelli G, Locatelli F, Daver N, Jabbour E, Kantarjian H, Konopleva M, Buccisano F, Ferrari A, Foà R, Galimberti S, Gottardi M, Iacobucci I, Isidori A, Lanza F, Martelli MP, Olivieri A, Pagano L, Papayannidis C, Quintarelli C, Rambaldi A, Ribera J, Rosti G

Day 0

15 march 2021

- 18.30 - 19.00 Lecture: How I manage Acute Myeloid Leukemia at MD Anderson Cancer Center - [H. Kantarjian](#)
- 19.00 - 19.30 Lecture: How I manage Acute Myeloid Leukemia in Europe - [G. Martinelli](#)
- 19.30 - 20.00 Lecture: How I manage Acute Lymphoblastic Leukemia at MD Anderson Cancer Center - [H. Kantarjian](#)
- 20.00 - 20.30 Lecture: How I manage Acute Lymphoblastic Leukemia in Europe - [G. Martinelli](#)
- 20.30 - 21.00 Lecture: How I manage pediatric Acute Leukemias - [F. Locatelli](#)

Day 1

16 March 2021

Frontal Session

- 08.30 - 08.50 Opening and introduction to the project:
[C. Cerchione](#) - [G. Martinelli](#)

Acute Lymphoblastic Leukemia

Biology and MRD Session in ALL: [C. Papayannidis](#), [A. Ferrari](#), [C. Quintarelli](#)

- 08.50 - 09.10 Impact of new opportunities in ALL biology - [C. Quintarelli](#)

- 09.10 - 09.30 Importance of MRD in ALL – [C. Papayannidis](#)
- 09.30 - 09.50 Adult Triple Negative B-ALL fusion landscape: new basis for potential treatments – [A. Ferrari](#)
- 09.50 - 10.00 break

Biology Session AML – [I. Iacobucci](#), [F. Buccisano](#), [G. Rosti](#)

- 10.00 - 10.20 New insights into AML Biology – [I. Iacobucci](#)
- 10.20 - 10.40 Molecular Pathogenesis of AML – [S. Galimberti](#)
- 10.40 - 11.00 Importance of MRD assessment and impact on treatment – [F. Buccisano](#)

Clinical Session ALL 1 – [G. Martinelli](#), [F. Locatelli](#), [F. Lanza](#)

- 11.00 - 11.20 How we manage ALL in daily practice in Europe – [G. Martinelli](#)
- 11.20 - 11.40 Role of monoclonal antibodies in relapsed/refractory ALL – [F. Lanza](#)
- 11.40 - 12.00 Near future of ALL – [R. Foà](#)
- 12.00 - 12.30 Discussion
- 12.30 - 13.30 **Lunch Symposium**

Clinical Session ALL 2 - H. Kantarjian, E. Jabbour, M. Konopleva

- 13.30 - 13.50 Major differences between Europe and USA in the management of ALL and AML - [H. Kantarjian](#)
- 13.50 - 14.10 Immunotherapy in adult and elderly ALL - [E. Jabbour](#)
- 14.10 - 14.30 How I manage Ph-positive ALL - [E. Jabbour](#)
- 14.30 - 14.50 How I manage Early T-cell precursors ALL and Ph-like ALL - [M. Konopleva](#)
- 14.50 - 15.10 CAR-T Clinical Trials in ALL - [F. Locatelli](#)
- 15.10 - 15.30 CAR Cytokine Induced Killer (CIK) Cells for Relapsed B-Cell Acute Lymphoblastic Leukemia - [A. Rambaldi](#)
- 15.30 - 15.50 Near future of CAR-T based approach in ALL - [J. Ribera](#)

Acute Myeloid Leukemia

Clinical Session AML 1 - C. Cerchione, N. Daver, F. Ravandi

- 15.50 - 16.10 How we manage AML in daily practice in Europe - [G. Martinelli](#)
- 16.10 - 16.30 How we integrate immunotherapy and target-therapies in AML management - [N. Daver](#)
- 16.30 - 16.50 Optimizing FLT3 inhibitor use in AML in 2021 - [N. Daver](#)
- 16.50 - 17.10 Novel antibodies in AML: new target therapies are possible - [F. Ravandi](#)
- 17.10 - 17.30 Role of IDH inhibitors in AML - [M.P. Martelli](#)
- 17.30 - 17.50 Role of CPX-351 in AML - [C. Cerchione](#)
- 17.50- 18.00 break

Clinical Session AML 1 - A. Isidori, M. Gottardi, A. Olivieri

- 18.00- 18.20 Elderly AML: present and future - A. Isidori
18.20 - 18.40 How we manage BDPCN as new entity - L. Pagano
18.40 - 19.00 Role of allogenic transplant in AML - A. Olivieri
19.00 - 19.20 Role of maintenance in AML - M. Gottardi

Near future of Acute Leukemias - G. Martinelli, H. Kantarjian

- 19.20 - 19.40 Near future of Acute Leukemias in USA - H. Kantarjian
19.40 - 20.00 Near future of Acute Leukemias in Europe - G. Martinelli

Day 2

17 March 2021

Young session

Selected oral presentations with project presentations in different categories

1st Session: Ferrari A, Iacobucci I, S. Galimberti, C. Quintarelli, C. Papayannidis,

- 08.30 - 09.00 Biology of ALL 1
09.00 - 09.30 Biology of ALL 2
09.30 - 10.00 Biology of AML 1
10.00 - 10.30 Biology of AML 2
10.30 - 11.00 MRD monitoring of acute leukemias
11.00 - 11.15 break

**2nd Session: R. Foà, M. Gottardi, MP Martelli, A. Olivieri, A. Isidori,
F. Buccisano, F. Lanza, L. Pagano, G. Rosti**

- 11.15 - 11.45 Allogenic transplant
- 11.45 - 12.15 CAR-T
- 12.15 - 12.45 Elderly patients
- 12.45 - 13.15 Supportive care of acute leukemias
- 13.15 - 13.45 Selected categories of patients and real life trials
- 13.45 - 15.00 **Symposium**

**3rd Session: H. Kantarjian, N. Daver, E. Jabbour, M. Konopleva,
F. Ravandi, F. Locatelli, J. Ribera**

- 15.00 - 15.30 Frontline treatment of AML
- 15.30 - 16.00 Relapsed/refractory treatment of AML
- 16.00 - 16.30 Frontline treatment of ALL
- 16.30 - 17.00 Relapsed/refractory treatment of ALL
- 17.00 - 17.30 Questions and answers and
discussion for future papers

After presentations, all projects will be started to be defined,
with their teams, objectives and timepoints

- 17.30 - 17.50 Conclusion and next steps

in associaton with



promoted by



supported by an unrestricted educational grant form



Follow us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOitLEUKEMIA

You can use it on Facebook, Twitter, Instagram and LinkedIn

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly
@SOHOitLEUKEMIA
@SocietyofHemOnc
@IRSTufficiale
@MDAndersonNews
@pro_eventi
@GMartinelli2
@DottorClaudio

Follow us!



#SOHOitLEUKEMIA

in association with



society of hematologic oncology

Promoted by



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico



SCHOOL

ACUTE LEUKEMIA

Clinical And Biological